Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
NCT02092961 · AstraZeneca · PHASE2 · terminated · last registry update 2014-06-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.” | – | Registry record, AstraZeneca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SYK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2014-12-18Results posted on the registry: Rigel Pharmaceuticals, fostamatinib (NCT00446095)
- 2014-08-22Results posted on the registry: AstraZeneca, Fostamatinib (NCT01499303)
- 2014-08-13Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib Disodium / R935788 (NCT00706342)
- 2014-06-25Results posted on the registry: AstraZeneca, Fostamatinib Disodium (R935788) (NCT00805467)
- 2014-06-25Also stopped (terminated): AstraZeneca, Fostamatinib Disodium (R935788) (NCT00805467)
- 2014-06-12Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib Disodium (NCT00798096)
- 2014-05-06Results posted on the registry: AstraZeneca, Fostamatinib and placebo injections + Fostamatinib and placebo injections (NCT01264770)
- 2014-05-06Also stopped (terminated): AstraZeneca, Fostamatinib and placebo injections + Fostamatinib and placebo injections (NCT01264770)
- 2014-04-17Results posted on the registry: AstraZeneca, fostamatinib + fostamatinib (NCT01197534)
- 2014-04-14Results posted on the registry: AstraZeneca, fostamatinib + placebo (NCT01563978)
- 2014-04-07Results posted on the registry: AstraZeneca, Fostamatinib + Fostamatinib (NCT01569074)
- 2014-04-07Also stopped (terminated): AstraZeneca, Fostamatinib + Fostamatinib (NCT01569074)
- 2014-04-07Results posted on the registry: AstraZeneca, fostamatinib + fostamatinib (NCT01197755)
- 2014-04-07Results posted on the registry: AstraZeneca, fostamatinib + fostamatinib (NCT01197521)
- 2014-04-04Results posted on the registry: AstraZeneca, Fostamatinib + Fostamatinib (NCT01242514)
- 2014-04-04Also stopped (terminated): AstraZeneca, Fostamatinib + Fostamatinib (NCT01242514)
- 2014-03-28Also stopped (terminated): AstraZeneca, Fostamatinib (NCT01640054)
- 2014-03-04Phase 3 first posted: Rigel Pharmaceuticals, Fostamatinib Disodium (NCT02077192)
- 2014-03-03Phase 3 first posted: Rigel Pharmaceuticals, Fostamatinib disodium + Placebo (NCT02076399)
- 2014-03-03Phase 3 first posted: Rigel Pharmaceuticals, Fostamatinib Disodium + Placebo (NCT02076412)
- 2014-01-09Results posted on the registry: AstraZeneca, Fostamatinib (NCT01640054)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision